Pharmacyclics, Inc.

Applera Corporation

Pharmacylics, Inc.

Cornell University

Joseph J Buggy

Erik J Verner

David J Loury

Tarak D Mody

Laurence Elias

Sriram Balasubramanian

Lee Honigberg

Gwen Fyfe

Wei Yu Chen

Eric Hedrick

Martin Sendzik

James Robinson

Chitra Baskaran

Norbert Purro

Chang-Sun Lee

Jun Chen

Vincent W F Tai

Betty Chang

Darren Magda

Richard A Miller

John C Byrd

Natarajan Muthusamy

Amy Jo Johnson

Susanne M Steggerda

Stéphane Depil

Jason A Dubovsky

Ioana Kloos

Shanthi Adimoolam

Craig Hill

Eric J Verner

Wei Chen

Richard Miller

Disclosed herein are methods for treating a cancer comprising: a. administering a Btk inhibitor to a subject sufficient to result in an increase or appearance in the blood of a subpopulation of lymphocytes defined by immunophenotyping; b. determining the expression profile of one or more biomarkers from one or more subpopulation of lymphocytes; and c. administering a second agent based on the determined expression profile.

Use of inhibitors of Brutons tyrosine kinase (Btk)

Described herein are mutations that confer resistance to treatment with a BTK inhibitor. Described herein are modified BTK polypeptides that exhibit decreased inhibition (i.e. are resistant) to a covalent and/or irreversible BTK inhibitor. Also described herein modifications of PLCy2 and CARD 11 polypeptides that confer resistance to treatment with a BTK inhibitor. Described herein are diagnostic methods for detecting the modified polypeptides and nucleic acids encoding the modified polypeptides and applications of the methods thereof. Described herein are compositions, combinations, and kits containing the modified polypeptides and methods of using the modified polypeptides. Also described herein are methods of using modified BTK polypeptides as screening agents for the identification and design of second-generation BTK inhibitors.

Mutations associated with resistance to inhibitors of Bruton's Tyrosine Kinase (BTK)

Use of inhibitors of Bruton's tyrosine kinase (Btk)

Use of inhibitors of bruton's tyrosine kinase (BTK)

Dosing regimens, methods of treatment, controlled release formulations, and combination therapies that include an HDAC inhibitor, or a pharmaceutically acceptable salt thereof, are described.

Formulations of histone deacetylase inhibitor and uses thereof

Described herein are methods and compositions for treating HER2-amplified cancer. The methods include administering to an individual in need thereof ibrutinib.

Methods for the treatment of HER2 amplified cancer

Use of inhibitors of Bruton'S tyrosine kinase (Btk)

Use of inhibitors of bruton's tyrosine kinase (Btk)

Described herein are irreversible Btk inhibitor compounds, and methods for using such irreversible inhibitors in the treatment of diseases and disorders characterized by the presence or development of solid tumors.

Inhibitors of Bruton's tyrosine kinase for the treatment of solid tumors

Described herein are methods and compositions comprising a covalent TEC family kinase inhibitor for use in adjuvant therapy, including adjuvant cancer therapy, vaccination and treatment of immune disorders and pathogenic infections.

TEC family kinase inhibitor adjuvant therapy

Growing community of inventors

Mountain View, CA, United States of America

Joseph J Buggy